Inhibitors for treating solid tumours
OwnerGareth THOMAS, Massimiliano MELLONEinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a new method of treating a solid tumour with an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 (checkpoint kinase 2) inhibitor. New therapy combinations, formulations and kits are also provided.
Claims25
A method of treating a solid tumour in a subject, the method comprising administering a therapeutically effective amount of an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor to the subject, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
A method of treating a solid tumour in a subject, the method comprising administering a therapeutically effective amount of:
- a) an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor;
- and
- b) at least one immunotherapeutic agent;
- to the subject, wherein the inhibitor and the at least one immunotherapeutic agent are administered simultaneously, separately or consecutively, and wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
A method of treating a solid tumour in a subject, the method comprising administering a therapeutically effective amount of an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor to the subject, wherein the subject is undergoing treatment with, has been treated with, or has been prescribed treatment with at least one immunotherapeutic agent, and wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
An ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor for use in treating a solid tumour, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
A method of treating a solid tumour in a subject, the method comprising administering a therapeutically effective amount of at least one immunotherapeutic agent to the subject, wherein the subject is undergoing treatment with, has been treated with, or has been prescribed treatment with an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor, and wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
An ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor for use in treating a solid tumour in combination with at least one immunotherapeutic agent, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
An immunotherapeutic agent for use in treating a solid tumour in combination with an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
An ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor in combination with at least one immunotherapeutic agent for use in treating a solid tumour, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
A pharmaceutical formulation comprising an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor, together with at least one immunotherapeutic agent, and at least one pharmaceutically acceptable excipient.
A kit comprising two separate formulations to be used together, the formulations being:
- a) a first formulation comprising an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor and at least one pharmaceutically acceptable excipient;
- and
- b) a second formulation comprising at least one immunotherapeutic agent and at least one pharmaceutically acceptable excipient.
A method for promoting T-cell infiltration and antitumour immunity of a solid tumour in a subject, comprising subjecting the subject to a therapeutically effective amount of an ATM (ataxia telangiectasia mutated) inhibitor and/or a CHK2 inhibitor in combination with at least one immunotherapeutic agent, wherein the solid tumour is a myofibroblastic cancer-associated fibroblast (myoCAF)-high or -moderate tumour.
Dependencies are inferred from the claim text.